Switch theme
Sign up to access all valuation multiples
Medplus Health Services Ltd is a pharmacy retailer. It offers pharmaceutical and wellness products such as medicines, vitamins, medical devices, test kits, and others. The company also offers an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility. Its operating segments include Retail, Diagnostics, and Others.
2006
1.2K+
LTM Revenue $732M
LTM EBITDA $59.2M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MedPlus India has a last 12-month revenue (LTM) of $732M and a last 12-month EBITDA of $59.2M.
In the most recent fiscal year, MedPlus India achieved revenue of $719M and an EBITDA of $62.7M.
MedPlus India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MedPlus India valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $732M | XXX | $719M | XXX | XXX | XXX |
| Gross Profit | $181M | XXX | $175M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $59.2M | XXX | $62.7M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $29.3M | XXX | $27.8M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $18.7M | XXX | $17.6M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MedPlus India's stock price is INR 968 (or $11).
MedPlus India has current market cap of INR 116B (or $1.4B), and EV of INR 123B (or $1.4B).
See MedPlus India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.4B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MedPlus India has market cap of $1.4B and EV of $1.4B.
MedPlus India's trades at 2.0x EV/Revenue multiple, and 24.5x EV/EBITDA.
Equity research analysts estimate MedPlus India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MedPlus India has a P/E ratio of 72.6x.
See valuation multiples for MedPlus India and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 24.3x | XXX | 24.5x | XXX | XXX | XXX |
| EV/EBIT | 48.9x | XXX | 58.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 72.6x | XXX | 89.8x | XXX | XXX | XXX |
| EV/FCF | 33.0x | XXX | 32.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedPlus India's last 12 month revenue growth is 11%
MedPlus India's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
MedPlus India's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MedPlus India's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MedPlus India and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MedPlus India acquired XXX companies to date.
Last acquisition by MedPlus India was XXXXXXXX, XXXXX XXXXX XXXXXX . MedPlus India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MedPlus India founded? | MedPlus India was founded in 2006. |
| Where is MedPlus India headquartered? | MedPlus India is headquartered in India. |
| How many employees does MedPlus India have? | As of today, MedPlus India has 1.2K+ employees. |
| Who is the CEO of MedPlus India? | MedPlus India's CEO is Mr. Gangadi Madhukar Reddy. |
| Is MedPlus India publicy listed? | Yes, MedPlus India is a public company listed on BOM. |
| What is the stock symbol of MedPlus India? | MedPlus India trades under 543427 ticker. |
| When did MedPlus India go public? | MedPlus India went public in 2021. |
| Who are competitors of MedPlus India? | Similar companies to MedPlus India include e.g. SC Ropharma, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of MedPlus India? | MedPlus India's current market cap is $1.4B |
| What is the current revenue of MedPlus India? | MedPlus India's last 12 months revenue is $732M. |
| What is the current revenue growth of MedPlus India? | MedPlus India revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of MedPlus India? | Current revenue multiple of MedPlus India is 2.0x. |
| Is MedPlus India profitable? | Yes, MedPlus India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MedPlus India? | MedPlus India's last 12 months EBITDA is $59.2M. |
| What is MedPlus India's EBITDA margin? | MedPlus India's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of MedPlus India? | Current EBITDA multiple of MedPlus India is 24.3x. |
| What is the current FCF of MedPlus India? | MedPlus India's last 12 months FCF is $43.5M. |
| What is MedPlus India's FCF margin? | MedPlus India's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of MedPlus India? | Current FCF multiple of MedPlus India is 33.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
